FI108722B - Menetelmä terapeuttisesti käyttökelpoisten 4a,5,9,10,11,12-heksahydro-11-metyyli-6H-bentsofuro[3a,3,2-ef][2]bentsatsepiini-3,6-diolin alkyylikarbonyyli- ja alkoksikarbonyylijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten 4a,5,9,10,11,12-heksahydro-11-metyyli-6H-bentsofuro[3a,3,2-ef][2]bentsatsepiini-3,6-diolin alkyylikarbonyyli- ja alkoksikarbonyylijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI108722B
FI108722B FI944823A FI944823A FI108722B FI 108722 B FI108722 B FI 108722B FI 944823 A FI944823 A FI 944823A FI 944823 A FI944823 A FI 944823A FI 108722 B FI108722 B FI 108722B
Authority
FI
Finland
Prior art keywords
hydrogen
formula
compound
give
alkylcarbonyl
Prior art date
Application number
FI944823A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI944823A (fi
FI944823A0 (fi
Inventor
Larry Davis
Veronica Taberna
Jr Raymond W Kosley
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of FI944823A0 publication Critical patent/FI944823A0/fi
Publication of FI944823A publication Critical patent/FI944823A/fi
Application granted granted Critical
Publication of FI108722B publication Critical patent/FI108722B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI944823A 1993-10-15 1994-10-13 Menetelmä terapeuttisesti käyttökelpoisten 4a,5,9,10,11,12-heksahydro-11-metyyli-6H-bentsofuro[3a,3,2-ef][2]bentsatsepiini-3,6-diolin alkyylikarbonyyli- ja alkoksikarbonyylijohdannaisten valmistamiseksi FI108722B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13744493 1993-10-15
US08/137,444 US6316439B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (3)

Publication Number Publication Date
FI944823A0 FI944823A0 (fi) 1994-10-13
FI944823A FI944823A (fi) 1995-04-16
FI108722B true FI108722B (fi) 2002-03-15

Family

ID=22477461

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944823A FI108722B (fi) 1993-10-15 1994-10-13 Menetelmä terapeuttisesti käyttökelpoisten 4a,5,9,10,11,12-heksahydro-11-metyyli-6H-bentsofuro[3a,3,2-ef][2]bentsatsepiini-3,6-diolin alkyylikarbonyyli- ja alkoksikarbonyylijohdannaisten valmistamiseksi

Country Status (23)

Country Link
US (1) US6316439B1 (da)
EP (1) EP0649846B1 (da)
JP (1) JP2664343B2 (da)
KR (1) KR100227957B1 (da)
CN (1) CN1039910C (da)
AT (1) ATE211474T1 (da)
AU (1) AU696170B2 (da)
CA (1) CA2118172C (da)
CZ (1) CZ283731B6 (da)
DE (1) DE69429570T2 (da)
DK (1) DK0649846T3 (da)
EG (1) EG20726A (da)
ES (1) ES2170759T3 (da)
FI (1) FI108722B (da)
IL (1) IL111275A (da)
NO (1) NO307464B1 (da)
NZ (1) NZ264682A (da)
PL (1) PL177549B1 (da)
PT (1) PT649846E (da)
RO (1) RO114134B1 (da)
RU (1) RU2109743C1 (da)
TW (1) TW289754B (da)
ZA (1) ZA948061B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
JP2005503345A (ja) * 2001-04-30 2005-02-03 バイエル・コーポレーシヨン 新規な４−アミノ−５，６−置換チオフェノ［２，３−ｄ］ピリミジン
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
CN101087618A (zh) * 2004-12-23 2007-12-12 航行药物公司 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
EP2137192B8 (en) 2008-04-14 2014-06-11 Neurodyn Life Sciences Inc. Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
US20110098278A1 (en) * 2009-07-23 2011-04-28 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
US11219627B2 (en) * 2014-05-16 2022-01-11 Synaptec Development Llc Clearance of amyloid beta
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3856594D1 (de) * 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
NZ242744A (en) 1991-05-14 1997-02-24 Ernir Snorrason Use of a cholinesterase inhibitor (eg a galanthamine derivative) for treating fatigue
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
EP0649846A1 (en) 1995-04-26
TW289754B (da) 1996-11-01
NO943895D0 (no) 1994-10-14
JP2664343B2 (ja) 1997-10-15
AU7581394A (en) 1995-05-04
NZ264682A (en) 1995-07-26
DE69429570D1 (de) 2002-02-07
KR100227957B1 (ko) 1999-11-01
DK0649846T3 (da) 2002-04-15
ES2170759T3 (es) 2002-08-16
DE69429570T2 (de) 2002-08-29
EP0649846B1 (en) 2002-01-02
NO943895L (no) 1995-04-18
RU94036745A (ru) 1996-12-10
RU2109743C1 (ru) 1998-04-27
FI944823A (fi) 1995-04-16
CA2118172C (en) 2000-01-04
EG20726A (en) 1999-12-29
PL305457A1 (en) 1995-04-18
PL177549B1 (pl) 1999-12-31
CZ254594A3 (en) 1995-07-12
AU696170B2 (en) 1998-09-03
NO307464B1 (no) 2000-04-10
CN1039910C (zh) 1998-09-23
IL111275A0 (en) 1994-12-29
CA2118172A1 (en) 1995-04-16
PT649846E (pt) 2002-06-28
FI944823A0 (fi) 1994-10-13
ZA948061B (en) 1995-06-06
RO114134B1 (ro) 1999-01-29
CN1108657A (zh) 1995-09-20
IL111275A (en) 2003-01-12
ATE211474T1 (de) 2002-01-15
CZ283731B6 (cs) 1998-06-17
JPH07188239A (ja) 1995-07-25
KR950011445A (ko) 1995-05-15
US6316439B1 (en) 2001-11-13

Similar Documents

Publication Publication Date Title
FI108722B (fi) Menetelmä terapeuttisesti käyttökelpoisten 4a,5,9,10,11,12-heksahydro-11-metyyli-6H-bentsofuro[3a,3,2-ef][2]bentsatsepiini-3,6-diolin alkyylikarbonyyli- ja alkoksikarbonyylijohdannaisten valmistamiseksi
FI108724B (fi) Menetelmä terapeuttisesti käyttökelpoisten 4a,5,9,10,11,12-heksahydro-11-metyyli-6H-bentsofuro[3a,3,2-ef][2]bentsatsepiini-3,6-diolin karbamoyylioksijohdannaisten ja niiden farmaseuttisesti hyväksyttävien happoadditiosuolojen valmistamiseksi
FI108723B (fi) Menetelmä terapeuttisesti käyttökelpoisten 4a,5,9,10,11,12-heksahydro-11-metyyli-6H-bentsofuro[3a,3,2-ef][2]bentsatsepiini-3,6-diolin 6-esterijohdannaisten valmistamiseksi
AU659027B2 (en) Substituted thienyl- or pyrrolylcarboxyclic acid derivatives, their preparation and medicines containing them
CZ410791A3 (en) Amides of thieno-triazolo-1,4-diazepino-2-carboxylic acid, process of their preparation and pharmaceutical preparation based thereon
UA61102C2 (uk) Сполука тетрагідропіридину та лікарський засіб на її основі
FI90240B (fi) Menetelmä terapeuttisesti aktiivisten 8-aminosubstituoitu-7,8-dihydro-6,6-dimetyyli-6H-pyrano/2,3-f/bentso-2,1,3-oksadiatsolien valmistamiseksi
US4210660A (en) Benzamide derivatives
FI89801B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva kinolinderivat
EP0413300A1 (en) Pyrido [3,4-b][1,4] benzoxazepines, a process for their preparation and their use as medicaments
FI74471C (fi) Foerfarande foer framstaellning av 6-aminoderivat av 3-benzyliden-pyrrolo/2,1-b/kinazoliner.
US5336679A (en) Tetrahydroimidazopyridine derivatives and salts thereof
US4963685A (en) Intermediates for the preparation of tetrahydroisoquino[2,1-c][1,3]benzodiazepines

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: HOECHST MARION ROUSSEL, INC.

PC Transfer of assignment of patent

Owner name: AVENTISUB II INC.

Free format text: AVENTISUB II INC.

MA Patent expired